Psoriasis Clinical Trials in Detroit
View 40 new treatments for Psoriasis in Detroit, MI, and nearby areas, such as Sterling Heights. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Auburn Hills + 4 more
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Waitlist
Phase 4
Est. 4 - 6 Weeks
Bristol-Myers Squibb
Study Director
Deucravacitinib for Scalp Psoriasis
Bristol-Myers Squibb Clinic, Bloomfield Hills + 2 more
This trial is testing a medication called deucravacitinib to see if it can help people with moderate-to-severe scalp psoriasis. The medication works by blocking proteins that cause inflammation and immune responses, which are responsible for the red, itchy, and scaly patches on the scalp. The goal is to find out if this treatment is safe and effective.Show More
Waitlist
Phase 4
Est. 6 - 12 Weeks
Bristol-Myers Squibb
Study Chair
Spesolimab for Pustular Psoriasis
Boehringer Ingelheim Clinic, Auburn Hills + 1 more
This study is open to adults with a serious skin disease called generalized pustular psoriasis (GPP) who have repeated flares of GPP. The purpose of this study is to find out whether a medicine called spesolimab helps people with repeated flares of GPP. Participants are given a single dose of spesolimab as an infusion into a vein on the first day of an outbreak of GPP. They may be given a second dose 1 week later if doctors think it is helpful. They are also treated for additional GPP flares. During the time of the study, doctors regularly examine participants' skin for signs of GPP to see how well the treatment works and take blood samples. The doctors also regularly check participants' health and take note of any unwanted effects.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Ann Arbor + 4 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Detroit + 2 more
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director
Apremilast for Pediatric Plaque Psoriasis
Amgen Clinic, Detroit + 1 more
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
MD
Study Director
Deucravacitinib for Psoriatic Arthritis
Bristol-Myers Squibb Clinic, Detroit + 2 more
This trial is testing a new medication called deucravacitinib to see if it can help people with psoriatic arthritis who haven't tried advanced treatments. The medication works by reducing joint swelling and pain by blocking inflammation. Deucravacitinib is a new oral drug that has shown good results in previous studies for psoriasis.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director
JNJ-77242113 for Plaque Psoriasis
Janssen Clinic, Troy + 2 more
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Janssen Research & Development, LLC Clinicaltrial
Study Director
ESK-001 for Psoriasis
Alumis Clinic, Clarkston + 2 more
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Certolizumab Pegol for Plaque Psoriasis
UCB Biopharma Clinic, Clarkston + 2 more
The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
UCB Cares
Study Director
Page 1 of 3
Frequently Asked Questions
Explore related conditions